Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review

BACKGROUND: Denosumab has become the preferred agent over zolendronic acid to help prevent skeletal-related events in patients with metastatic bone disease and multiple myeloma because it is approved for use in those with kidney dysfunction. However, denosumab has been linked to cases of hypocalcemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marlow, Christina F., Sharma, Shailendra, Babar, Faizan, Lin, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204163/
https://www.ncbi.nlm.nih.gov/pubmed/30405927
http://dx.doi.org/10.1155/2018/2059364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204163/
https://www.ncbi.nlm.nih.gov/pubmed/30405927
http://dx.doi.org/10.1155/2018/2059364

Ejemplares similares